SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Daisuke Kodama, Akifumi Togari, Signaling pathway and physiological role of the alpha-1 adrenergic receptor in human osteoblasts, Journal of Oral Biosciences, 2014, 56, 3, 73

    CrossRef

  2. 2
    Sian Yik Lim, Pavis Laengvejkal, Ragesh Panikkath, Kenneth Nugent, Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures, The American Journal of the Medical Sciences, 2013, 1

    CrossRef

  3. 3
    D Kodama, A Togari, Noradrenaline stimulates cell proliferation by suppressing potassium channels via Gi/o-protein-coupled α1B-adrenoceptors in human osteoblasts, British Journal of Pharmacology, 2013, 168, 5
  4. 4
    Katarina Ilić, Nevena Obradović, Nada Vujasinović-Stupar, The Relationship Among Hypertension, Antihypertensive Medications, and Osteoporosis: A Narrative Review, Calcified Tissue International, 2013, 92, 3, 217

    CrossRef

  5. 5
    William J. Elliott, James L. Pool, Hypertension: A Companion to Braunwald’s Heart Disease, 2013,

    CrossRef

  6. 6
    Nadir I Osman, Christopher R Chapple, Francisco Cruz, François Desgrandchamps, Carlos Llorente, Francesco Montorsi, Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia, Expert Opinion on Pharmacotherapy, 2012, 13, 14, 2085

    CrossRef

  7. 7
    Miguel Araujo, Estudios sobre los eventos adversos de las intervenciones, Medwave, 2011, 11, 09

    CrossRef

  8. 8
    P. Vestergaard, L. Rejnmark, L. Mosekilde, Risk of fractures associated with treatment for benign prostate hyperplasia in men, Osteoporosis International, 2011, 22, 2, 731

    CrossRef

  9. 9
    P Hiitola, H Enlund, R Kettunen, R Sulkava, S Hartikainen, Postural changes in blood pressure and the prevalence of orthostatic hypotension among home-dwelling elderly aged 75 years or older, Journal of Human Hypertension, 2009, 23, 1, 33

    CrossRef

  10. 10
    Joongyub Lee, Nam-Kyoung Choi, Sun-Young Jung, Ye-Jee Kim, Jong-Mi Seong, Seung-June Oh, Byung-Joo Park, The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia, Journal of Preventive Medicine and Public Health, 2009, 42, 3, 165

    CrossRef

  11. You have free access to this content11
    Debra A Schwinn, Claus G Roehrborn, α1-Adrenoceptor subtypes and lower urinary tract symptoms, International Journal of Urology, 2008, 15, 3
  12. 12
    Gillian C Hall, Alex D McMahon, Comparative study of modified release alpha-blocker exposure in elderly patients with fractures, Pharmacoepidemiology and Drug Safety, 2007, 16, 8
  13. 13
    S. Hartikainen, E. Lonnroos, K. Louhivuori, Medication as a Risk Factor for Falls: Critical Systematic Review, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2007, 62, 10, 1172

    CrossRef

  14. 14
    William J. Elliott, James L. Pool, Hypertension, 2007,

    CrossRef

  15. 15
    Martin C. Michel, Christopher R. Chapple, Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL), European Urology, 2006, 49, 3, 501

    CrossRef

  16. 16
    M. WIENS, M. ETMINAN, S. S. GILL, B. TAKKOUCHE, Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies, Journal of Internal Medicine, 2006, 260, 4
  17. 17
    Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Michael Shear, Jonathan Davies, Adrian Quartel, Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation, European Urology Supplements, 2005, 4, 2, 53

    CrossRef

  18. 18
    Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Michael Shear, Jonathan Davies, Adrian Quartel, Comparison of Vascular α1-Adrenoceptor Antagonism of Tamsulosin in Oral Controlled Absorption System (OCAS) and Modified Release (MR) Formulations, European Urology Supplements, 2005, 4, 2, 45

    CrossRef

  19. 19
    Gerard W.K. Hugenholtz, Eibert R. Heerdink, Tjeerd P. van Staa, Willem A. Nolen, Antoine C.G. Egberts, Risk of hip/femur fractures in patients using antipsychotics, Bone, 2005, 37, 6, 864

    CrossRef

  20. 20
    Christopher R. Chapple, Salman H. Al-Shukri, Bernard Gattegno, Simon Holmes, José M. Martínez-Sagarra, Roberto M. Scarpa, Oncko B. van Vierssen Trip, Viktor Vik, Ingrid van der Putten-Slob, Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study, European Urology Supplements, 2005, 4, 2, 33

    CrossRef

  21. 21
    Mark Speakman, The Clinical Development of Omnic (Tamsulosin) Oral Controlled Absorption System (OCAS®), European Urology Supplements, 2005, 4, 7, 5

    CrossRef

  22. 22
    Cees Korstanje, The Improved Cardiovascular Safety of Omnic (Tamsulosin) Oral Controlled Absorption System (OCAS®), European Urology Supplements, 2005, 4, 7, 10

    CrossRef

  23. 23
    Maurits M. Barendrecht, Richard P. Koopmans, Jean J.M.C.H. De La Rosette, Martin C. Michel, Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system, BJU International, 2005, 95,
  24. 24
    Walter Artibani, Integrating the Patient Risk Profile in the Management of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH), European Urology Supplements, 2004, 3, 4, 1

    CrossRef

  25. 25
    Bob Djavan, α1-Adenoceptor Antagonists for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): State of the Art, European Urology Supplements, 2004, 3, 4, 23

    CrossRef

  26. 26
    Debra A. Schwinn, David T. Price, Perinchery Narayan, α1-Adrenoceptor Subtype Selectivity and Lower Urinary Tract Symptoms, Mayo Clinic Proceedings, 2004, 79, 11, 1423

    CrossRef

  27. 27
    Masaki Yoshida, Imao Mikoshiba, Katsuyoshi Akiyama, Junzo Kudoh, Silodosin (Urief®, Rapaflo®, Thrupas®, Urorec®, Silodix™): A Selective α1A Adrenoceptor Antagonist for the Treatment of Benign Prostatic Hyperplasia,